Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2004 December;46(4) > Panminerva Medica 2004 December;46(4):227-37

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

REVIEWS  


Panminerva Medica 2004 December;46(4):227-37

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Blood pressure and dementia

Birkenhäger W. H. 1, Staessen J. A. 2

1 Erasmus University, Rotterdam, the Netherlands* 2 Study Coordinating Centre, Hypertension Unit University of Leuven, Belgium


PDF  


Hypertension has proven to be a major predisposing factor for the development of both vascular and degenerative (Alzheimer’s) dementias, either following stroke or gradually through more insidious microcerebrovascular processes. In the latter case the interval between the respective manifestations of hypertension and dementia may vary between a few years and several decades. The temporal relationships may become complicated by the finding that blood pressure tends to fall shortly before the onset of overt Alzheimers’ disease. Whether or not timely antihypertensive regimens may delay or even prevent the development of dementias later in life is still an “educated” guess, as long there has been no comprehensive trial comparing the potential of the different antihypertensive drug classes in this regard. Until then, the class of dihydropyridine calcium antagonists (exemplified by nitrendipine in the Syst-Eur trial) is the only category having statistically been proven to be of substantial value for prevention of Alzheimer’s disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail